-Reuters
AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data
AstraZeneca plc (NASDAQ:AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies…